(Albany, New York)- 10th Sep 2026 – DelveInsight’s latest report, “Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast – 2034,” provides a comprehensive analysis of the Antibody Drug Conjugates (ADC) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates current treatment practices, emerging ADC therapies, market shares of individual therapies, historical and forecasted market trends, target patient populations, and unmet medical needs from 2020 to 2034.

Antibody-drug conjugates are becoming increasingly prominent in oncology, combining the antigen specificity of monoclonal antibodies with potent cytotoxic payloads. The growing adoption of targeted cancer therapies, expansion into multiple tumor types, advances in antibody and linker technologies, and a broad pipeline of clinical-stage ADCs are expected to create significant opportunities across the seven major markets through 2034.

Key Takeaways from the Antibody Drug Conjugates Market

• The Antibody Drug Conjugates market is forecast to evolve significantly during 2025–2034, supported by increasing development and expansion of ADC therapies across a wide range of indications.

• More than 200 ADCs are in preclinical or clinical development, highlighting the rapid expansion of this therapeutic modality.

• The current US FDA-approved ADC landscape includes KADCYLA, ADCETRIS, BESPONSA, EMRELIS, LUMOXITI, POLIVY, PADCEV, TRODELVY, ENHERTU, BLENREP, ZYNLONTA, TIVDAK, and ELAHERE.

• Four ADCs have been granted FDA approval specifically for breast cancer: KADCYLA, ENHERTU, TRODELVY, and DATROWAY.

• ENHERTU generated nearly USD 1,470 million in US sales in 2023, while KADCYLA generated approximately USD 760 million in the US during the same year.

• The report covers ADC applications across breast cancer, lung cancer, hematologic malignancies, gynecologic cancers, and other indications.

• Key emerging therapies include Patritumab deruxtecan, Ifinatamab deruxtecan, Telisotuzumab vedotin, Luveltamab tazevibulin, ARX788, AZD8205, Raludotatug deruxtecan, and Farletuzumab ecteribulin.

• Leading companies include AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Roche, Sutro Biopharma, Ambrx, Pyxis Oncology, Vincerx Pharma, Byondis, OBI Pharma, NBE-Therapeutics, ADC Therapeutics, and others.

Keen to know more about the Antibody Drug Conjugates Market Report?https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market

Key Factors Driving the Antibody Drug Conjugates Market

Increasing Adoption of Targeted Cancer Therapies

ADCs are designed to selectively deliver cytotoxic payloads to tumor cells by combining a tumor-targeting antibody with a potent drug through a chemical linker. This approach is intended to improve therapeutic selectivity compared with conventional chemotherapy and potentially widen the therapeutic window.

Expanding Applications Across Multiple Cancer Types

The clinical development of ADCs is expanding beyond established indications such as HER2-positive breast cancer. Current development programs are targeting NSCLC, ovarian cancer, multiple myeloma, DLBCL, cervical cancer, urothelial cancer, and other solid and hematologic malignancies, creating opportunities for broader market penetration.

Advances in ADC Technology

Improvements in antibody engineering, linker chemistry, payload selection, target identification, and drug-to-antibody ratios are supporting the development of increasingly sophisticated ADCs. These advances are enabling developers to explore new tumor antigens and improve efficacy while attempting to manage treatment-related toxicities.

Strong Pipeline and Increasing Clinical Development

The ADC pipeline continues to expand rapidly, with numerous candidates progressing through Phase II and Phase III development. Candidates such as Patritumab deruxtecan, Ifinatamab deruxtecan, Telisotuzumab vedotin, and Raludotatug deruxtecan are being evaluated across multiple cancer indications, potentially creating new treatment options and market opportunities.

Increasing Strategic Investments and Collaborations

Major pharmaceutical companies are increasingly entering collaborations and acquisitions to strengthen their ADC portfolios. For example, AbbVie completed its USD 10.1 billion acquisition of ImmunoGen in February 2024, gaining ELAHERE and additional ADC candidates, while Daiichi Sankyo and Merck entered a global development and commercialization agreement covering three DXd ADC candidates.

Competitive Landscape

The Antibody Drug Conjugates market consists of an expanding portfolio of marketed therapies and a large pipeline of emerging candidates.

Marketed ADCs include ENHERTU, ADCETRIS, KADCYLA, PADCEV, ELAHERE, TIVDAK, EMRELIS, POLIVY, TRODELVY, BLENREP, ZYNLONTA, BESPONSA, and LUMOXITI. These therapies target a diverse range of tumor-associated antigens, including HER2, CD30, Nectin-4, FRα, Tissue Factor, c-Met, and others.

Among emerging therapies, Telisotuzumab vedotin (ABBV-399) from AbbVie is being evaluated in NSCLC, Patritumab deruxtecan (HER3-DXd) from Daiichi Sankyo/Merck is being developed for EGFR-mutated NSCLC, and Ifinatamab deruxtecan is being investigated across multiple solid tumors, including small cell lung cancer and esophageal squamous cell carcinoma.

Other important pipeline candidates include Luveltamab tazevibulin, ARX788, AZD8205, Raludotatug deruxtecan, and Farletuzumab ecteribulin.

Recent Developments in the Antibody Drug Conjugates Market

• August 2026: GlycoNex Inc. dosed the first patient in a Phase I clinical trial of GNX1021, a first-in-class glycan-directed ADC being developed for advanced or refractory solid tumors.

• June 2026: ADC Therapeutics announced a strategic global restructuring that included an approximately 17% workforce reduction, with resources being focused on the development and regulatory pathway of ZYNLONTA.

• May 2026: Piramal Pharma Solutions unveiled a new payload-linker manufacturing suite at its Riverview, Michigan facility to expand its ADC development and manufacturing capabilities.

• September 2025: Raludotatug deruxtecan (R-DXd) received Breakthrough Therapy Designation from the US FDA for CDH6-expressing platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab.

• May 2025: Merck announced the voluntary withdrawal of the US BLA for patritumab deruxtecan based on the HERTHENA-Lung01 Phase II trial.

• February 2025: Pfizer announced US FDA approval of an sBLA for ADCETRIS in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma, including DLBCL.

What are Antibody Drug Conjugates?

Antibody-drug conjugates (ADCs) are targeted medicines composed of three principal components: an antibody, a linker, and a cytotoxic payload. The antibody is designed to recognize a specific antigen expressed on tumor cells, while the linker connects the antibody to the cytotoxic payload.

Following binding to the target antigen, the ADC is internalized into the tumor cell. Subsequent linker breakdown releases the cytotoxic payload intracellularly, where it can exert microtubule-disrupting or DNA-damaging effects. The antibody component may also contribute to anticancer activity through mechanisms such as antibody-dependent cellular cytotoxicity.

This targeted mechanism aims to combine the specificity of monoclonal antibodies with the potent cell-killing activity of cytotoxic drugs, potentially reducing nonspecific exposure associated with conventional chemotherapy.

Current Treatment Landscape

The ADC treatment landscape has expanded considerably since the approval of the first ADC, MYLOTARG. Although MYLOTARG was voluntarily withdrawn from the market in 2017 following confirmatory studies that raised concerns regarding clinical benefit and safety, subsequent generations of ADCs have demonstrated substantial clinical and commercial potential.

ENHERTU, KADCYLA, ADCETRIS, PADCEV, TRODELVY, ELAHERE, TIVDAK, POLIVY, ZYNLONTA, BLENREP, BESPONSA, LUMOXITI, and EMRELIS represent important components of the currently approved ADC landscape in the United States.

Despite their therapeutic advantages, ADCs are associated with unique toxicities and require careful patient monitoring. Continued development is therefore focused on improving target specificity, linker stability, payload characteristics, therapeutic index, and resistance management.

Antibody Drug Conjugates Epidemiology Segmentation

The Antibody Drug Conjugates epidemiology analysis covers:

• Total Incident Cases of Potential ADC Indications, including non-small cell lung cancer, hematologic malignancies, breast cancer, gynecologic cancers, and others

• Total Indication-wise Eligible Cases

• Indication-wise Treatable Cases

According to DelveInsight, selected indication-specific epidemiological data include approximately 300,000 incident breast cancer cases in the US in 2024, nearly 200,000 incident NSCLC cases, approximately 34,000 multiple myeloma cases, and around 31,000 DLBCL cases. The estimated incidence of ovarian cancer in Japan was approximately 13,000 cases in 2024.

Scope of the Antibody Drug Conjugates Market Report

• Study Period: 2020–2034

• Forecast Period: 2025–2034

• Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and Japan

• Market Segmentation: Region and Indication

• Epidemiology Segmentation: Total cases of selected indications for ADCs, total eligible patients of selected indications, and total treated cases in selected indications

• Key Companies Covered: AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Roche, Sutro Biopharma, Ambrx, Pyxis Oncology, Vincerx Pharma, Byondis, OBI Pharma, NBE-Therapeutics, Shanghai Miracogen, ADC Therapeutics, and others

• Key Marketed Therapies Covered: ELAHERE, TIVDAK, ENHERTU, PADCEV, EMRELIS, KADCYLA, ADCETRIS, TRODELVY, POLIVY, BLENREP, ZYNLONTA, BESPONSA, and LUMOXITI

• Key Emerging Therapies Covered: Patritumab deruxtecan, Ifinatamab deruxtecan, Telisotuzumab vedotin, Luveltamab tazevibulin, ARX788, AZD8205, Raludotatug deruxtecan, Farletuzumab ecteribulin, Datopotamab deruxtecan, MRG003, Camidanlumab tesirine, NBE-002, OBI-999, BYON3521, CC-99712, VIP-943, PYX-201, PYX-203, and others

• Market Assessment: Historical and forecasted ADC market size, market size by therapies, market size by indication, market share, pricing trends, cost assumptions, analogue assessment, launch timing, and therapy uptake

• Clinical Development Assessment: Clinical trials, pharmacological action, collaborations, licensing agreements, regulatory milestones, patent information, advantages and disadvantages, and recent developments

• Qualitative Analysis: SWOT analysis, conjoint analysis, KOL views, treatment preferences, efficacy, safety, administration frequency, route of administration, probability of success, and addressable patient pool

• Market Access and Reimbursement: Country-wise accessibility, reimbursement scenarios, cost-effectiveness, patient assistance programs, insurance coverage, and out-of-pocket affordability

• Report Insights: ADC patient pool, therapeutic approaches, pipeline analysis, market size, market trends, and existing and future market opportunities

• Key Strengths: Eleven-year market forecast, 7MM coverage, epidemiology segmentation, market size analysis, drug uptake, pipeline therapies, market drivers, market barriers, and forecast assumptions.

To know more about the clinical trials, emerging therapies, competitive landscape, and therapeutic assessment of Antibody Drug Conjugate Market Therapies:View the Antibody Drug Conjugates Market Report

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Methodology

6. Antibody Drug Conjugates Market Overview

7. Disease Background and Overview of Antibody Drug Conjugates

8. Treatment Landscape

9. Epidemiology

10. Marketed Therapies

11. Emerging Therapies

12. ADC Seven Major Market Analysis

13. SWOT Analysis

14. KOL Views

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/